首页> 外文期刊>Clinical Genetics: An International Journal of Genetics in Medicine >Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia.
【24h】

Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia.

机译:在患有遗传性出血性毛细血管扩张的德国患者中,检测到ACVRL1基因突变与肝脏受累之间的显着相关性。

获取原文
获取原文并翻译 | 示例
           

摘要

Hereditary haemorrhagic telangiectasia (HHT) is a heterogeneous multisystemic dysplasia of the vascular tissue. This autosomal dominant inherited disorder shows a wide variation in its phenotypic expression. Between 8 and 78% of the HHT patients show arteriovenous malformations of the liver. The molecular basis for hepatic manifestation is still unknown. Two genes are known to play a major role in the development of HHT: activin A receptor type II-like 1 gene (ACVRL1) and ENG. Previously, we and others showed that hepatic involvement is associated with mutations in the ACVRL1 gene, but rarely caused by ENG mutations. Here, we report about the sequencing analysis of a new cohort of 18 adult HHT patients. In these patients, we identified eight novel (four in ACVRL1 and four in ENG) and eight already known mutations. Statistical analysis of our entire data revealed significant differences in the distribution of ACVRL1 and ENG mutations among HHT patients with and without liver involvement (p = 0.0016). The positive predictive value for type 2 HHT (ACVRL1 positive) patients to develop liver disease until the age of 52 years is 68.4%. We conclude that molecular genetic testing of HHT patients is important for prognosis with respect to liver disease.
机译:遗传性出血性毛细血管扩张(HHT)是血管组织的异质性多系统性异型增生。这种常染色体显性遗传疾病在其表型表达上表现出很大的差异。 8%至78%的HHT患者显示出肝动静脉畸形。肝表现的分子基础仍然未知。已知两个基因在HHT的发展中起主要作用:激活素A受体II型1基因(ACVRL1)和ENG。以前,我们和其他人表明,肝脏受累与ACVRL1基因的突变有关,但很少由ENG突变引起。在这里,我们报告了有关18名成年HHT患者新队列的测序分析。在这些患者中,我们鉴定出八种新突变(ACVRL1中四种,ENG中四种)和八种已知突变。对我们全部数据的统计分析显示,在有和没有肝脏受累的HHT患者中,ACVRL1和ENG突变的分布存在显着差异(p = 0.0016)。直到52岁,发展为肝病的2型HHT(ACVRL1阳性)患者的阳性预测值为68.4%。我们得出结论,HHT患者的分子遗传学检测对于肝病的预后非常重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号